McAdory John Bearden 4

What Happened John Bearden McAdory, Chief Operating Officer of Oncolytics Biotech Inc. (ONCY), received a grant of derivative awards on June 1, 2026: options covering 145,000 shares. The filing lists the acquisition price as $0.00 because this is an option grant (not a cash purchase); the exercise (strike) price is equal to the closing price of ONCY common stock on the Nasdaq on the grant date (June 1, 2026). This is an award/compensation event rather than an open-market purchase or sale.

Key Details

• Transaction type: Award/Grant of options (derivative), reported on Form 4 for period 2026-06-01; filing date 2026-06-03.
• Quantity and price: 145,000 option shares; exercise price = closing price on Nasdaq on 2026-06-01 (grant date). Filing shows $0.00 because it’s a grant.
• Vesting: Options vest in three equal annual installments, with first tranche vesting June 1, 2027, subject to continued service. (Footnotes F1 and F2.)
• Shares owned after transaction: Not disclosed in the provided filing data.
• Timeliness: Filing was submitted two days after the grant (appears timely; no late filing flag reported).

Context This is a typical executive equity compensation grant. Because the strike price equals the market close on the grant date, the options are effectively at-the-money at grant. No shares were exercised or sold in this transaction; any future exercise would require payment of the strike price (or use of company-approved exercise procedures). Such grants compensate and retain executives and do not by themselves indicate buying or selling sentiment.